LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Penumbra Inc

Fermé

SecteurSoins de santé

338.48 -0.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

337.48

Max

340.45

Chiffres clés

By Trading Economics

Revenu

-176M

-130M

Ventes

31M

385M

P/E

Moyenne du Secteur

81.89

66.845

Marge bénéficiaire

-33.822

Employés

4,700

EBITDA

13M

68M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+9.64% upside

Dividendes

By Dow Jones

Prochains Résultats

22 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

122M

13B

Ouverture précédente

339.01

Clôture précédente

338.48

Sentiment de l'Actualité

By Acuity

67%

33%

306 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Penumbra Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 janv. 2026, 13:29 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 janv. 2026, 12:35 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 janv. 2026, 12:29 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

25 févr. 2026, 18:02 UTC

Résultats

Penumbra: Won't Be Providing Financial Guidance for 2026, Citing Proposed Boston Scientific Deal

25 févr. 2026, 18:01 UTC

Résultats

Penumbra 4Q Rev $385.4M >PEN

25 févr. 2026, 18:01 UTC

Résultats

Penumbra 4Q Adj EPS $1.18 >PEN

25 févr. 2026, 18:01 UTC

Résultats

Penumbra 4Q EPS $1.20 >PEN

24 janv. 2026, 06:18 UTC

Acquisitions, Fusions, Rachats

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15 janv. 2026, 14:37 UTC

Actions en Tendance

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 janv. 2026, 13:45 UTC

Acquisitions, Fusions, Rachats

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 janv. 2026, 12:04 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 janv. 2026, 12:03 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 janv. 2026, 12:01 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 janv. 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 janv. 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Comparaison

Variation de prix

Penumbra Inc prévision

Objectif de Prix

By TipRanks

9.64% hausse

Prévisions sur 12 Mois

Moyen 372.36 USD  9.64%

Haut 374 USD

Bas 360 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

15 ratings

3

Achat

12

Maintien

0

Vente

Score Technique

By Trading Central

288.28 / 292.9394Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

306 / 351Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat